Why the study?
Does mid-regional pro-adrenomedullin (MR-proADM) measurement improve the diagnosis and prognosis of patients with sepsis and septic shock?
Population
Patients with sepsis and septic shock, including subpopulations with burns or malignant tumors
Design
Review
Key result
Mid-regional pro-adrenomedullin (MR-proADM) is a useful biomarker for the diagnosis and mortality prognosis of sepsis and septic shock, with area under the curve values exceeding 0.8.
Authors
Loading...
May aid sepsis assessment; hypothesis-generating and requires RCT validation before adoption.
Does mid-regional pro-adrenomedullin (MR-proADM) measurement improve the diagnosis and prognosis of patients with sepsis and septic shock?
MR-proADM is a promising biomarker for the diagnosis and prognosis of sepsis, septic shock, and organ failure, though further validation in randomized controlled trials is needed.
Önal et al. (2018) conducted a review in Sepsis and septic shock. Mid-regional pro-adrenomedullin (MR-proADM) was evaluated on Diagnosis and prognosis of sepsis and septic shock. Mid-regional pro-adrenomedullin (MR-proADM) is a useful biomarker for the diagnosis and mortality prognosis of sepsis and septic shock, with area under the curve values exceeding 0.8.